AR-882 is under clinical development by Arthrosi Therapeutics and currently in Phase II for Gouty Arthritis (Gout). According to GlobalData, Phase II drugs for Gouty Arthritis (Gout) have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AR-882’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AR-882 overview

AR-882 is under development for the treatment of gout and hyperuricemia. It is formulated as suspension and administered through oral route. It acts by targeting uric acid transporter 1 (URAT1).

Arthrosi Therapeutics overview

Arthrosi Therapeutics (Arthrosi) is the biotech company that carries out drug development and discovery. It focused on the development of therapy for gout and chronic kidney disease. Arthrosi’s product Portfolio includes gout, refractory tophaceous gout, chronic kidney disease and non-small cell lung cancer. The proprietary molecule, AR882, designed to lower uric acid, diminish tophi, and reduce gout flares – without renal safety issues. AR882 is a potent uricosuric drug undergoing development for the treatment of gout. It operates in Australia and China. Arthrosi is headquartered in San Diego, California, the US.

For a complete picture of AR-882’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.